Algert Global LLC lowered its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 67.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,240 shares of the biopharmaceutical company's stock after selling 25,116 shares during the period. Algert Global LLC's holdings in Agios Pharmaceuticals were worth $402,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently modified their holdings of the company. Summit Investment Advisors Inc. boosted its stake in Agios Pharmaceuticals by 7.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock valued at $194,000 after purchasing an additional 394 shares during the period. Federated Hermes Inc. raised its stake in Agios Pharmaceuticals by 4.4% during the 4th quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock worth $450,000 after buying an additional 582 shares during the period. KBC Group NV raised its stake in Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 611 shares during the period. Alliancebernstein L.P. raised its stake in shares of Agios Pharmaceuticals by 1.2% in the fourth quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock worth $2,021,000 after purchasing an additional 708 shares during the last quarter. Finally, Atria Investments Inc grew its stake in Agios Pharmaceuticals by 6.9% in the 4th quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock valued at $373,000 after purchasing an additional 737 shares during the period.
Analyst Ratings Changes
Several analysts have weighed in on the company. HC Wainwright initiated coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a "buy" rating and a $58.00 price target on the stock. StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, May 10th. Finally, Scotiabank lowered their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Agios Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $56.00.
View Our Latest Analysis on Agios Pharmaceuticals
Insider Buying and Selling
In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. This trade represents a 4.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.30% of the stock is currently owned by company insiders.
Agios Pharmaceuticals Price Performance
NASDAQ:AGIO traded up $0.92 during trading hours on Friday, reaching $29.18. The company's stock had a trading volume of 771,981 shares, compared to its average volume of 697,807. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The business's 50-day moving average is $28.81 and its 200-day moving average is $36.57. The company has a market cap of $1.69 billion, a price-to-earnings ratio of 2.57 and a beta of 0.77.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. The business had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.
Agios Pharmaceuticals Company Profile
(
Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Featured Articles
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
